Navigation Links
LifeVantage Announces Settlement of Zrii Litigation
Date:12/18/2009

dependent distributors or to attract new independent distributors on an ongoing basis; the potential for third party and governmental actions involving the Company's network marketing sales channel; the potential for product liability claims against the Company; the risk that government regulators and regulations could adversely affect the Company's business; future laws or regulations may hinder or prohibit the production or sale of the Company's existing product and any future products; unfavorable publicity could materially hurt the Company's business; and the Company's ability to protect its intellectual property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption "Risk Factors", and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.


    Investor Relations Contact:
    Ioana C. Hone
    (858) 312-8000 Ext. 4

SOURCE LifeVantage Corporation


'/>"/>
SOURCE LifeVantage Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. LifeVantage Announces Fourth Quarter and Fiscal Year 2009 Financial and Operating Results
2. LifeVantage Announces Preliminary Unaudited First Quarter Revenue
3. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
(Date:9/1/2014)... shows on TV may be bad for your waistline, a ... while watching action films and programs than something less exciting, ... if you,re watching an action movie while snacking your mouth ... the Cornell Food and Brand Lab, said in a university ... is, the more you will eat." The study included ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 An operating ... a hospital for performing surgical operations. An operating room ... tables, surgical booms, operating room lights, imaging displays as ... a report by Transparency Market Research, a U.S.-based market ... to reach USD 4.5 billion by 2019. , ...
(Date:9/1/2014)... 01, 2014 The B-cell non-Hodgkin’s Lymphoma ... six major markets (the US, France, Italy, Germany, Spain ... $5.41 billion by 2018. , The competitive landscape in ... Germany, Spain and the UK is poised to undergo ... of the four largest B-cell NHL indications, which includes ...
(Date:9/1/2014)... 1 September 2014: Permanent atrial fibrillation (AF) doubles the ... research in more than 6 000 patients presented at ... The findings suggest that a simple clinical assessment of ... estimate stroke risk. , Ischaemic stroke is the second ... a million deaths and many more disabled patients each ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3
... ... will help you transform the way employees engage inside and outside of the workplace. ... Milwaukee, Wisc. (PRWEB) February 1, ... event “Aligning the Corporate and Personal Brand,” hosted by Loyola University in Chicago. ...
... who took the course were more likely to delay having ... who took abstinence-only sex education classes were more likely to ... study, some 662 black 6th- and 7th-grade students, ranging in ... 12, participated in classes held on Saturdays at four Philadelphia ...
... memory skills after 12 weeks of treatment, researchers report ... after a stroke may help repair the damaged brain ... Little has been shown to help the brain restore ... initial stroke treatment. But a University of Iowa study ...
... Surprise finding may have implications for labor anesthesia, orthopedics and ... One of the holy grails of local anesthesia is the ability ... not affecting motor function. Now, researchers at Children,s Hospital Boston have ... it proves to work in humans as well as it did ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
... , Proposed projects will combat global ... Kiwanis International is searching for its next global cause, ... Service Project finalists: Global Network for Neglected Tropical Diseases for ... the Canadian Red Cross for their joint malaria proposal; and ...
Cached Medicine News:Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3Health News:Antidepressants After Stroke May Boost Mental Ability 2Health News:Antidepressants After Stroke May Boost Mental Ability 3Health News:Anesthetic Approach Stops Pain Without Affecting Motor Function 2Health News:Anesthetic Approach Stops Pain Without Affecting Motor Function 3Health News:FDA Announces Safety Risk Associated with HIV Drug 2Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 2Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 3Health News:Kiwanis Selects Three Finalists for Worldwide Service Project 4
Designated most popular model or size. Double-ended. 2 mm wide....
Designated most popular model or size. Slightly angled, 2 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Desmarres Infant Retractor...
Medicine Products: